vVARDIS Holding AG, a dental medtech company focused on non-invasive approaches to caries management, has announced a strategic minority investment from funds managed by Apollo (Apollo Funds).
The investment is intended to support the company’s continued global expansion, including broader availability of its Curodont™ product line. Following the transaction, vVARDIS remains privately held, with founders and co-CEOs Drs. Haley and Goly Abivardi retaining a majority ownership stake.
vVARDIS’ Curodont™ technology represents a non-invasive approach to managing early carious lesions. The peptide-based formulations are designed to support enamel remineralization by facilitating the formation of a crystalline mineral structure within affected areas. This provides clinicians with an additional option for managing early-stage decay without operative intervention.
Curodont™ Repair Fluoride Plus has been available in the United States for more than 2 years and has reportedly been used in the treatment of approximately 3 million teeth. The product has seen adoption across general dental practices and is among a group of rapidly expanding products in the preventive and early intervention segment.
“vVARDIS has built a differentiated business, with Drs. Haley and Goly Abivardi pioneering a new category in dental care backed by peer-reviewed clinical studies,” said Jeremy Honeth, Partner and Andrea Vanni, Managing Director at Apollo. “Apollo Funds’ investment supports the company’s continued expansion in key markets across the United States and Europe, bringing this restorative therapy to more practices and patients worldwide.”
“Curodont™ fills a longstanding gap in dentistry: when prevention fails, dentists now have a quick, easy-to-use non-invasive treatment free of drilling and needles. The rapid adoption of Curodont™ reflects the urgency of that unmet need,” said Haley Abivardi, DMD, co-CEO and co-founder of vVARDIS. “Apollo Funds’ investment strengthens our commercial foundation in the United States and Europe and enables us to scale this environmentally sustainable technology across markets.”
Goly Abivardi, DMD, co-CEO and co-founder of vVARDIS, said, “Our mission is to bring a medical, science-driven approach to dentistry. Using peptide-containing formulations, our non-invasive technology is an innovative treatment designed to treat tooth decay without drilling and without polymer materials. Apollo Funds’ investment reinforces our leadership in generative dentistry and advances the future of oral science.”
Dental caries remains highly prevalent, affecting a substantial proportion of the global population, including the majority of adults in the United States. Untreated lesions are associated with broader health implications, reinforcing the clinical emphasis on early detection and minimally invasive management. Recent WHO guidance has similarly emphasized early intervention and non-invasive care pathways.
Financial terms of the investment were not disclosed.
Figures and Images
Curodont™
Drs. Haley and Goly Abivardi
